Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STSP-0902 Ophthalmic Solution in Healthy Subjects
NCT06597422Phase 1Completed
- Sponsor
- Staidson Biopharmaceutical
- Start
- Oct 2024
- Primary completion
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of STSP-0902 in neurotrophic keratitis (NK) (10 arms), sponsored by Staidson Biopharmaceutical. Primary endpoint: Incidence of Adverse Events related to study drug at Day 28. Started Oct 2024; status: completed.
02
Drugs
STSP-0902
03
Conditions
neurotrophic keratitis (NK)
Beyond the preview
Go deeper on NCT06597422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06597422.